EUVIMEDEUVIMED entdecken
Open Access

A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans

Saravanan Raju iD, Lucas J Adams iD, James T Earnest iD, Kelly Warfield iD, Lo Vang iD, James E Crowe iD, Daved H Fremont iD, Michael S Diamond iD

Science Translational Medicine · 2023

DOI: 10.1126/scitranslmed.ade8273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Saravanan Raju und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever, Vaccines, Virus-Like Particle. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to a CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained from a phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels of neutralizing antibody in serum against CHIKV and circulating antigen–specific B cells up to 6 months after immunization. Monoclonal antibodies (mAbs) generated from peripheral blood B cells of three PXVX0317-vaccinated individuals on day 57 after immunization potently neutralized CHIKV infection, and a subset of these inhibited multiple related arthritogenic alphaviruses. Epitope mapping and cryo–electron microscopy defined two broadly neutralizing mAbs that uniquely bind to the apex of the B domain of the E2 glycoprotein. These results demonstrate the inhibitory breadth and activity of the human B cell response induced by the PXVX0317 vaccine against CHIKV and potentially other related alphaviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya virusChikungunya FeverVaccines, Virus-Like ParticleAnimalsHumansCryoelectron MicroscopyAntibodies, ViralAntibodies, NeutralizingAntibodies, Monoclonal

Substanzen

Vaccines, Virus-Like ParticleAntibodies, ViralAntibodies, NeutralizingAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Emergent BioSolutions, Gaithersburg, MD 20879, USA.
  • Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

ORCID-Profile: Saravanan Raju, Lucas J Adams, James T Earnest, Kelly Warfield, Lo Vang, James E Crowe, Daved H Fremont, Michael S Diamond

Förderung

  • NIAID NIH HHS

Zitieren

APA

Raju, S., Adams, L. J., Earnest, J. T., Warfield, K., Vang, L., Crowe, J. E., Fremont, D. H., & Diamond, M. S. (2023). A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ade8273

Vancouver

Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE, et al. A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.ade8273

BibTeX
@article{Raju2023,
  author = {Raju, Saravanan and Adams, Lucas J and Earnest, James T and Warfield, Kelly and Vang, Lo and Crowe, James E and Fremont, Daved H and Diamond, Michael S},
  title = {A chikungunya virus–like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans},
  journal = {Science Translational Medicine},
  year = {2023},
  doi = {10.1126/scitranslmed.ade8273}
}
Kostenlos starten →